US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology: market research reports

RSS Feeds

CNS/Neurology market research reports and industry analysis

1  2    4    6  7  8  9  10  
Low-Grade Glioma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... information and data relating to the clinical trials on Low-Grade Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Malignant Glioma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Pontine Glioma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... information and data relating to the clinical trials on Pontine Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Market Highlights: Spain Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Spain. The research includes Spain attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Germany Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Germany. The research includes Germany attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: France Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in France. The research includes France attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Japan Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Japan. The research includes Japan attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Europe Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... disorder drug sales forecast for Germany, France, Italy, Spain, and UK. The research includes Europe (Germany, France, Italy, Spain, and UK) attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six ...  |  read more...
USD 2,800
Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
USD 2,500
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... information and data relating to the clinical trials on Recurrent Medulloblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
PharmaPoint: Migraine - Current and Future Players
3/31/2014 | published by: GlobalData
... the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies ...  |  read more...
USD 2,995
Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Opium (Opioid) Addiction - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Alcohol Addiction - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Autism - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Cognitive Impairment - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
1  2    4    6  7  8  9  10